July 26, 2021, 10:08 AM EDT R&D
John Carroll
Editor & Founder
AbbVie picked up some bonus points earlier this year as one of its pipelines adds from the $63 billion Allergan buyout hit its top-line marks. And now the researchers have produced the detailed data on the case they are making with regulators, with an eye on a major new market and a hoped-for approval before New Year’s.
AGN-190584 is aiming to be the first easy-on-eyedrop for presbyopia, a common ailment for large numbers of people who find it harder and harder to read things like a watch or cell phone close up. Anyone who’s held a book out at arm’s length in order to read it will be very familiar with the condition, if not the exact diagnosis.
Their Phase III study — Gemini I — came up with some convincing proof that the eyedrops deliver fast though transient improvements in reading ability, with a statistically significant group of patients adding 3 lines or more when viewing a reading chart.
AbbVie’s team turned up at the 2021 American Society of Cataract and Refractive Surgery annual meeting to showcase the data, which includes a generally clean bill of health on safety.
“While not often known by name, the 128 million Americans living with presbyopia feel the condition’s impact throughout their daily lives, often when looking at their cell phones, reading, or trying to see a menu in a dimly lit restaurant. Additionally, our ever-increasing time spent on digital devices, from smartwatches to smartphones, has put unprecedented demands on our vision,” said George O. Waring IV, the GEMINI principal study investigator.
Leave a Reply